$3.21
5.03%
Nasdaq, Oct 15, 04:00 pm EDT. Closed.
ISIN
US45257L1089
Symbol
IMMP

Immutep Ltd Sponsored ADR Stock price

$3.21
-3.40 51.41% 1M
-7.67 70.50% 6M
-53.99 94.39% YTD
-39.19 92.43% 1Y
-33.19 91.18% 3Y
-75.79 95.94% 5Y
-56.12 94.59% 10Y
-799.46 99.60% 20Y
Nasdaq, Closing price Thu, Oct 15 2026
-0.17 5.03%
ISIN
US45257L1089
Symbol
IMMP
Industry

Is Immutep Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$25.5m
Enterprise Value
$-21.4m
Net debt
positive
Cash
$47.7m
Shares outstanding
1.5b
Valuation
P/E
negative
P/S | estimate
2.5 | 7.0
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
negative | negative
P/B
0.6
Financial Health
Equity Ratio
73.9%
Return on Equity
-128.9%
ROCE
-125.8%
ROIC
-1,061.5%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$300.0k | 3.0%
SBC as % of FCF
6.4%
SBC Growth 1Y
-63.0%
Share Count Growth 1Y
0.9%
Shareholder Yield
-0.9%
Financials
Revenue | estimate
$10.1m | $3.6m
EBITDA
-
EBIT
$-60.2m
Net Income
$-54.9m
Free Cash Flow | ex SBC
$4.7m | $4.4m
Growth
Revenue | estimate
25,150.0% | -64.1%
EBITDA
-
EBIT
-24.0%
Net Income
-29.1%
Free Cash Flow
110.9%
Margin
Gross
-
EBITDA
-
EBIT
-595.7%
Net
-543.4%
Free Cash Flow | ex SBC
46.3% | 43.4%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
1.4%
Employees
31
Rev per Employee
$330.0k

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

4x Buy
50%
4x Hold
50%

Analyst Opinions

8 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy
50%
Hold
50%

Financial data from Immutep Ltd Sponsored ADR

Jun '26
+/-
%
10 10
25,150% 25,150%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.63 6.63
11% 11%
66%
- Research and Development Expense 64 64
50% 50%
630%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -60 -60
24% 24%
-596%
Net Profit -55 -55
29% 29%
-544%

In millions USD.

Don't miss a Thing! We will send you all news about Immutep Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immutep Ltd Sponsored ADR Stock News

Neutral
GlobeNewsWire
●
16 days ago
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on el...
Neutral
GlobeNewsWire
●
3 months ago
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co. Inc., Rahway, NJ, USA) anti-PD-1 therap...
Neutral
PRNewsWire
●
4 months ago
LOS ANGELES, June 15, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class peri...
More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office Australia
CEO Mr. Voigt
Employees 31
Founded 1987
Website www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today